

Fara BrasÃ³-Maristany

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/210775/publications.pdf>

Version: 2024-02-01

25
papers

1,064
citations

623734

14
h-index

642732

23
g-index

25
all docs

25
docs citations

25
times ranked

1688
citing authors

#	ARTICLE	IF	CITATIONS
1	PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. <i>Nature Medicine</i> , 2016, 22, 1303-1313.	30.7	188
2	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 45.	5.0	175
3	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	6.3	97
4	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	7.7	92
5	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 67, 63-70.	7.7	79
6	Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. <i>Journal of Clinical Oncology</i> , 2021, 39, 1458-1467.	1.6	73
7	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020, 11, 385.	12.8	67
8	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	10.7	52
9	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 4871-4887.	8.2	49
10	Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer. <i>Nature Communications</i> , 2018, 9, 1044.	12.8	39
11	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 1902.	3.7	29
12	Gene expression profiles of breast cancer metastasis according to organ site. <i>Molecular Oncology</i> , 2022, 16, 69-87.	4.6	24
13	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. <i>Clinical Cancer Research</i> , 2020, 26, 3720-3731.	7.0	21
14	Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. <i>Science Advances</i> , 2022, 8, .	10.3	21
15	High <i>FGFR1</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 137-149.	7.0	12
16	Biomarkers of immunotherapy response in breast cancer beyond PD-L1. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 39-49.	2.5	11
17	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021, 69, 103451.	6.1	7
18	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6141-6148.	7.0	6

#	ARTICLE	IF	CITATIONS
19	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 313.	8.6	6
20	14-gene immunoglobulin (IGG) and proliferation signatures and association with overall survival across cancer-types.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2636-2636.	1.6	6
21	Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 710596.	2.8	5
22	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. <i>Frontiers in Immunology</i> , 2021, 12, 792609.	4.8	3
23	Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. <i>Annals of Hematology</i> , 2021, 100, 2997-3005.	1.8	2
24	Abstract PS10-02: A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies. , 2021, , .		0
25	Abstract OT1-12-01: Solti-1804 HER2-PREDICT: Translational study of tumor samples from breast cancer patients treated with trastuzumab deruxtecan in the metastatic setting. <i>Cancer Research</i> , 2022, 82, OT1-12-01-OT1-12-01.	0.9	0